
Ibrahim Celalettin Haznedaroǧlu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1450945/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Review on Characteristics and Analytical Methods of Rivaroxaban. Critical Reviews in Analytical Chemistry, 2022, 52, 865-877.	3.5	9
2	Prophylactic Central Nervous System Irradiation Is Not Indispensable In Adult Patients With Acute Lymphoblastic Leukemia: A Multi-Center Retrospective Cohort Study. Turkish Journal of Haematology, 2022, , .	0.5	0
3	Bone Marrow Origin of Coronary Artery Diseases: The Impact of the Local Renin-Angiotensin System Acta Cardiologica Sinica, 2022, 38, 13-20.	0.2	Ο
4	Four-Dimensional Echocardiographic Evaluation of Left Ventricular Systolic Functions in Patients with Chronic Myeloid Leukaemia Receiving Tyrosine Kinase Inhibitors. Cardiovascular Toxicology, 2021, 21, 216-223.	2.7	4
5	Convalescent plasma therapy in patients with COVID-19. Transfusion and Apheresis Science, 2021, 60, 102955.	1.0	52
6	The clinical course of COVID-19 in hematopoietic stem cell transplantation (HSCT) recipients. Turkish Journal of Medical Sciences, 2021, 51, 1647-1652.	0.9	7
7	Evaluation of Prognostic Significance of the International Staging System According to Glomerular Filtration Rate in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation. Turkish Journal of Haematology, 2021, 38, 33-40.	0.5	8
8	Perspectives for immune plasma treatment of COVID-19. Turkish Journal of Medical Sciences, 2021, 51, 1-9.	0.9	4
9	Could Targeting HMGB1 be Useful for the Clinical Management of COVID-19 Infection?. Combinatorial Chemistry and High Throughput Screening, 2021, 24, 587-590.	1.1	3
10	Allogeneic Hematopoietic Stem-Cell Transplantation Improves Disease-Free Survival Compared to Pediatric-Inspired Berlin-Frankfurt-Münster Chemotherapy in Adult Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 147-153.	0.4	5
11	Leukemic stem cells shall be searched in the bone marrow before "tyrosine kinase inhibitorâ€discontinuationâ€in chronic myeloid leukemia. International Journal of Laboratory Hematology, 2021, 43, 1110-1116.	1.3	6
12	Long-term results of allogeneic peripheral blood hematopoietic stem cell transplantation for severe aplastic anemia. Transfusion and Apheresis Science, 2021, 60, 103050.	1.0	1
13	Efficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in Turkey. Turkish Journal of Medical Sciences, 2021, 51, 1033-1042.	0.9	Ο
14	Free Health Coverage for All COVID-19 Patients is Required to Defeat the Virus at The Community Level. Acta Medica, 2021, 52, 90-91.	0.2	0
15	Exposure of Hepatocellular Carcinoma Cells to Ankaferd Blood Stopper® Alters Cell Death Signaling Networks Confirmed by Oncoproteomic and Genomic Profiling Studies. Current Traditional Medicine, 2021, 7, 246-258.	0.4	8
16	Covid-19 scientific publications from Turkey. Turkish Journal of Medical Sciences, 2021, 51, 877-889.	0.9	7
17	Current community transmission and future perspectives on the COVID-19 process. Turkish Journal of Medical Sciences, 2021, 51, 1001-1011.	0.9	1
18	Antitumor activity of Ankaferd Blood Stopper® on MCF-7 breast cancer: A proteomic approach to ascertain the mechanism of the action. Journal of Herbal Medicine, 2021, 28, 100449.	2.0	1

#	Article	IF	CITATIONS
19	Human Ace D/I Polymorphism Could Affect the Clinicobiological Course of COVID-19. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2021, 2021, 1-7.	1.7	20
20	Protein Kinases in Hematological Disorders. Advances in Experimental Medicine and Biology, 2021, 1275, 383-393.	1.6	5
21	Clinical variations between three different causes of thrombocytopenia. Nigerian Journal of Clinical Practice, 2021, 24, 17.	0.6	4
22	Predictive factors for stem cell mobilization failure in multiple myeloma patients: A single center experience. Transfusion and Apheresis Science, 2020, 59, 102595.	1.0	6
23	The comparison of bone marrow kinetics between patients with acute myeloid leukemia and acute promyelocytic leukemia after induction chemotherapy. Immunopharmacology and Immunotoxicology, 2020, 42, 17-21.	2.4	1
24	Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content. Medical Hypotheses, 2020, 143, 110150.	1.5	3
25	Antiinfective and wound-healing pleiotropic actions of Ankaferd hemostat. Turkish Journal of Medical Sciences, 2020, 50, 1434-1435.	0.9	4
26	Pathobiological Interactions of Local Bone Marrow Renin-Angiotensin System and Central Nervous System in Systemic Arterial Hypertension. Frontiers in Endocrinology, 2020, 11, 425.	3.5	13
27	Immunogenomic phases of COVID-19 and appropriate clinical management. Lancet Microbe, The, 2020, 1, e278.	7.3	3
28	Comparison of bortezomib-cyclophosphamide-dexamethasone versus bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients. Hematology Reports, 2020, 12, 8267.	0.8	1
29	Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis. Transfusion and Apheresis Science, 2020, 59, 102821.	1.0	42
30	In vitro analysis of the renin–angiotensin system and inflammatory gene transcripts in human bronchial epithelial cells after infection with severe acute respiratory syndrome coronavirus. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2020, 21, 147032032092887.	1.7	12
31	Spontaneous subepithelial hemorrhage of renal pelvis and ureter (Antopol-Goldman lesion) in hemophilia A patient with inhibitor. Medicine (United States), 2020, 99, e20851.	1.0	8
32	The effects of blood group types on the risk of COVID-19 infection and its clinical outcome. Turkish Journal of Medical Sciences, 2020, 50, 679-683.	0.9	139
33	Pharmacobiological management of hemostasis within clinical backgrounds via Ankaferd hemostat (Ankaferd blood stopper). SAGE Open Medicine, 2020, 8, 205031212090781.	1.8	4
34	Renin angiotensin system genes are biomarkers for personalized treatment of acute myeloid leukemia with Doxorubicin as well as etoposide. PLoS ONE, 2020, 15, e0242497.	2.5	18
35	Ankaferd hemostat: from molecules to medicine. Turkish Journal of Medical Sciences, 2020, 50, 1739-1750.	0.9	4
36	Evaluation of the Survival Outcomes of Multiple Myeloma Patients According to Their Plasmacytoma Presentation at Diagnosis. Turkish Journal of Haematology, 2020, 37, 256-262.	0.5	11

#	Article	IF	CITATIONS
37	The impact of early versus late platelet and neutrophil recovery after induction chemotherapy on survival outcomes of patients with acute myeloid leukemia. Turkish Journal of Haematology, 2020, 37, 116-120.	0.5	8
38	Who 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors. Turkish Journal of Haematology, 2020, 37, 42-47.	0.5	8
39	COVID-19, Renin-angiotensin System and Hematopoiesis. Turkish Journal of Haematology, 2020, 37, 207-208.	0.5	1
40	CD34+ hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation. Turkish Journal of Medical Sciences, 2020, 50, 1851-1856.	0.9	7
41	Title is missing!. , 2020, 15, e0242497.		0
42	Title is missing!. , 2020, 15, e0242497.		0
43	Title is missing!. , 2020, 15, e0242497.		0
44	Title is missing!. , 2020, 15, e0242497.		0
45	Title is missing!. , 2020, 15, e0242497.		Ο
46	Title is missing!. , 2020, 15, e0242497.		0
47	Title is missing!. , 2020, 15, e0242497.		0
48	Title is missing!. , 2020, 15, e0242497.		0
49	Indications and outcomes of splenectomy for hematological disorders. Open Medicine (Poland), 2019, 14, 491-496.	1.3	4
50	A unique case of complex variant translocation of t(6;9;22)(p22;q34;q11.2), der(19) in a newly diagnosed patient with chronic myeloid leukemia. Cancer Genetics, 2019, 237, 78-81.	0.4	5
51	Unclassifiable non-CML classical myeloproliferative diseases with microcytosis: findings indicating diagnosis of polycythemia vera masked by iron deficiency. Turkish Journal of Medical Sciences, 2019, 49, 1560-1563.	0.9	3
52	Ghosal hematodiaphyseal dysplasia with autoimmune anemia in two adult siblings. Transfusion and Apheresis Science, 2019, 58, 449-452.	1.0	4
53	Mitoxantrone-melphalan conditioning regimen for autologous stem cell transplantation in relapsed/refractory lymphoma. Turkish Journal of Medical Sciences, 2019, 49, 985-992.	0.9	5
54	The factors affecting early death in newly diagnosed APL patients. Open Medicine (Poland), 2019, 14, 647-652.	1.3	19

#	Article	IF	CITATIONS
55	The impact of At1r inhibition via losartan on the anti-leukaemic effects of doxorubicin in acute myeloid leukaemia. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2019, 20, 147032031985131.	1.7	6
56	Analysis of the Antiproliferative Effect of Ankaferd Hemostat on Caco-2 Colon Cancer Cells via LC/MS Shotgun Proteomics Approach. BioMed Research International, 2019, 2019, 1-11.	1.9	7
57	The impact of JAK/STAT inhibitor ruxolitinib on the genesis of lymphoproliferative diseases. Turkish Journal of Medical Sciences, 2019, 49, 661-674.	0.9	6
58	Effects of Ankaferd Hemostat on red blood cell aggregation: a hemorheological study. Turkish Journal of Medical Sciences, 2019, 49, 356-360.	0.9	4
59	The Antithrombin Effect of Ankaferd Hemostat (ABS) Is Related to the High Iron Content of the Medicine. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961882441.	1.7	1
60	Branch retinal vein occlusion associated with platelet activation. Turkish Journal of Medical Sciences, 2019, 49, 283-287.	0.9	9
61	Effects of Ankaferd Hemostat on Helicobacter pylori strains and antibiotic resistance. Turkish Journal of Medical Sciences, 2019, 49, 347-355.	0.9	6
62	Current perspectives for the treatment of chronic myeloid leukemia. Turkish Journal of Medical Sciences, 2019, 49, 1-10.	0.9	21
63	Impact of Time Between Induction Chemotherapy and Complete Remission on Survival Outcomes in Patients With Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 729-734.	0.4	6
64	Efficacy and Feasibility of Allogeneic Hematopoietic Stem-Cell Transplantation in the Treatment of Refractory Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 177-182.	0.4	5
65	Comparison of Myeloablative Versus Reduced-Intensity Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: A Cohort Study. Turkish Journal of Haematology, 2019, 36, 88-96.	0.5	5
66	A multi-centric study on the efficacy of eltrombopag in management of refractory chronic immune thrombocytopenia. Turkish Journal of Haematology, 2019, 36, 230-237.	0.5	8
67	Aggressive Clinicopathological Course of Myeloma with t(3;16) (q21;q22) Cytogenetic Abnormality. Turkish Journal of Haematology, 2019, 36, 62-63.	0.5	0
68	TUMOR LYSIS SYNDROME DUE TO TARGETING OF HEPATOCELLULAR CARCINOMA ASSOCIATED WITH CHRONIC MYELOMONOCYTIC LEUKEMIA. Turkish Journal of Haematology, 2019, 36, 218-219.	0.5	2
69	Thrombosis and Bleeding in Philadelphia Negative Myeloproliferative Neoplasia: Incidences and Risk Factors. Acta Medica, 2019, 50, 1-7.	0.2	0
70	Effects of Smoking on Hematological Parameters and Ferritin Levels. Haseki Tip Bulteni, 2019, 57, 372-376.	0.3	2
71	Retrospective evaluation of chromosome 1 anomalies in hematologic malignancies: A single center study. Genetics & Applications, 2019, 3, 17.	0.1	0
72	Discontinuation of imatinib mesylate could improve renal impairment in chronic myeloid leukemia. Open Medicine (Poland), 2018, 14, 22-24.	1.3	5

#	Article	IF	CITATIONS
73	Effect of postremission high dose cytarabine-based consolidation chemotherapy before allogenic stem cell transplantation in outcomes of acute myeloid leukemia patients. Transfusion and Apheresis Science, 2018, 57, 752-755.	1.0	3
74	Frontline nilotinib treatment in Turkish patients with Philadelphia chromosome–positive chronic Myeloid Leukemia in chronic phase: updated results with 2 years of follow-up. Hematology, 2018, 23, 771-777.	1.5	5
75	On Being a â€~Physician Patient' With His Own Experimental Therapeutic Drug. Turkish Journal of Haematology, 2018, 35, 302-303.	0.5	4
76	Long-Term Results of Non- Fludarabine Versus Fludarabine-Based Conditioning Regimens in Severe Aplastic Anemia Patients. Blood, 2018, 132, 5700-5700.	1.4	0
77	Growth inhibitory activity of Ankaferd hemostat on primary melanoma cells and cell lines. SAGE Open Medicine, 2017, 5, 205031211668951.	1.8	15
78	Proteomic and transcriptomic analyses to explain the pleiotropic effects of Ankaferd blood stopper. SAGE Open Medicine, 2017, 5, 205031211772256.	1.8	11
79	The Modelled Effectiveness of Ruxolitinib on Survival in Polycythemia Patients with Hydroxyurea Resistance/Intolerance in Turkey. Value in Health, 2017, 20, A545.	0.3	1
80	Epidemiological Estimates and Treatment Practice Pattern in Polycythemia Vera Patients in Turkey: Results Based on an Expert Panel. Value in Health, 2017, 20, A546.	0.3	1
81	Lipotoxicity-Related Hematological Disorders in Obesity. Advances in Experimental Medicine and Biology, 2017, 960, 469-487.	1.6	3
82	Antibacterial Activities of Ankaferd Hemostat (ABS) on Shiga Toxin-Producing Escherichia coli and Other Pathogens Significant in Foodborne Diseases. Turkish Journal of Haematology, 2017, 34, 93-98.	0.5	4
83	Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms. Turkish Journal of Haematology, 2017, 34, 27-33.	0.5	10
84	Sole Infrequent Karyotypic Aberration Trisomy 6 in a Patient with Acute Myeloid Leukemia and Breast Cancer in Remission. Turkish Journal of Haematology, 2017, 34, 103-104.	0.5	2
85	Peripheral FLT-3 ligand levels as a pathobiological parameter duringthe clinical course of acute myeloid leukemia. Turkish Journal of Medical Sciences, 2016, 46, 1889-1893.	0.9	1
86	Qualitative/Chemical Analyses of Ankaferd Hemostat and Its Antioxidant Content in Synthetic Gastric Fluids. BioMed Research International, 2016, 2016, 1-8.	1.9	14
87	Treatment of pyoderma gangrenosum with thalidomide in a myelodysplastic syndrome case. International Medical Case Reports Journal, 2016, 9, 61.	0.8	7
88	Clinical associations, biological risk factors and outcomes of cerebral venous sinus thrombosis. Journal of International Medical Research, 2016, 44, 1454-1461.	1.0	35
89	Ultrastructural analyses of the novel chimeric hemostatic agent generated via nanotechnology, ABS nanohemostat, at the renal tissue level. SpringerPlus, 2016, 5, 1931.	1.2	3
90	Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase. Expert Opinion on Pharmacotherapy, 2016, 17, 1851-1858.	1.8	6

#	Article	IF	CITATIONS
91	Reply. Annals of Pharmacotherapy, 2016, 50, 336-336.	1.9	1
92	Comparison of Myelodysplastic Syndrome Prognostic Scoring Systems. Turkish Journal of Haematology, 2016, 33, 119-126.	0.5	4
93	The Prognosis of Adult Burkitt's Cell Leukemia in Real-Life Clinical Practice. Turkish Journal of Haematology, 2016, 33, 281-285.	0.5	3
94	Endothelial Cells, Ankaferd Hemostat, and Estradiol. Turkish Journal of Haematology, 2016, 33, 261-262.	0.5	1
95	Expression Profiles of the Individual Genes Corresponding to the Genes Generated by Cytotoxicity Experiments with Bortezomib in Multiple Myeloma. Turkish Journal of Haematology, 2016, 33, 286-292.	0.5	2
96	The Management of Chronic Myeloid Leukemia in the Era of Second Generation Tyrosine Kinase Inhibitors. UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, 2016, 26, 1-3.	0.1	1
97	Splenic artery embolization with Ankaferd blood stopper in a sheep model. Diagnostic and Interventional Radiology, 2016, 22, 354-357.	1.5	4
98	High iron content of Ankaferd hemostat as a clue for its hemostatic action of red blood cell origin. Blood Coagulation and Fibrinolysis, 2015, 26, 233-234.	1.0	6
99	Melanonychia Secondary to Long-Term Treatment with Hydroxycarbamide: An Essential Thrombocytosis Case. Case Reports in Hematology, 2015, 2015, 1-3.	0.4	Ο
100	DRUG THERAPY IN THE PROGRESSED CML PATIENT WITH MULTI-TKI FAILURE. Mediterranean Journal of Hematology and Infectious Diseases, 2015, 7, e2015014.	1.3	15
101	Management of De Novo CML and Imatinib-Induced Acute Rhabdomyolysis With the Second-Generation TKI, Dasatinib. Annals of Pharmacotherapy, 2015, 49, 740-742.	1.9	9
102	Bone marrow fibrosis may be an effective independent predictor of the †TKI drug response level' in chronic myeloid leukemia. Hematology, 2015, 20, 392-396.	1.5	15
103	Rebound Thrombocytosis following Induction Chemotherapy Is an Independent Predictor of a Good Prognosis in Acute Myeloid Leukemia Patients Attaining First Complete Remission. Acta Haematologica, 2015, 134, 32-37.	1.4	12
104	MPV may reflect subcinical platelet activation in diabetic patients with and without diabetic retinopathy. Eye, 2015, 29, 376-379.	2.1	33
105	Severe radiation esophagitis successfully treated with Ankaferd hemostat. Gastrointestinal Endoscopy, 2015, 81, 1048-1049.	1.0	4
106	Tryptophan in Molecular Hematopoiesis. Molecular and Integrative Toxicology, 2015, , 253-267.	0.5	0
107	Clinical and pathological correlations of marrow PUMA and P53 expressions in myelodysplastic syndromes. Apmis, 2015, 123, 445-451.	2.0	5
108	High frequency of autonomous T-cell proliferation compatible with T-cell large granular lymphocytic leukemia in patients with cytopenia of unknown etiology. International Journal of Hematology, 2015, 102, 211-217.	1.6	2

110In Yoon Healing Effects of Arkaferd Effood Stopper on the Residual Parcreatic Tissue in a Swine Model0.33110Pharmacobiological Approach for the Clinical Development of Ruxolitinia in Myeloproliferative0.33111Chickopathelogical associations of acquired enythrobiology of acute myeloid leukemia. International1.31112Dhe factors affecting early death after the initial therapy of acute myeloid leukemia. International1.35113Applied Thrombasily Hemostask, 2015, 8, 22564-9.1.35114Iber factors affecting early death after the initial therapy of acute myeloid leukemia. International1.35115Applied Thrombasily Hemostask, 2015, 8, 22564-9.1.31.71116Iber factors affecting early death after the initial therapy of acute myeloid leukemia. International1.35117Involo confocial microscopic characteristics of crystalline beatopathy in patients with anonodonal1.117118Isomopathy, Report of throus dess. Indian Journal of Clinical and Lypopathelogy. 2014, 6, 2014009.1.36119Ibercased Soldble Solectina as a Reflection of Activated Platekts and Endottslum in theratocology. 2014, 6, 2014009.0.68119Ibercased Soluble Solectina as a Reflection of Activated Platekts and Endottslum in theratocology. 2014, 6, 2014009.0.68119Ibercased Soluble Solectin as a Reflection of Activated Platekts and Endottslum in theratocology. 2014, 6, 2014009.0.66120Pharletcrit. Herz, 2014, 39, 142.148.1.16.6121<	#	Article	IF	CITATIONS
110 Necoplasms. Turkish journal of Haematology, 2015, 32, 163-167. 0.3 5 111 Clinicopathological associations of acquired exythroblastopenia. International Journal of Clinical and Experimental Medicine, 2015, 8, 22515.9. 1.3 1 112 The factors affecting early death after the initial therapy of acute myeloid leukemia. International loarnal of Clinical and Experimental Medicine, 2015, 8, 22564.9. 1.3 5 113 Next Generation Nanomedicine in the Genesis of SecoAnkeferd Blood Stopper Nanohemostată-6 Clinical and 1.7 1 114 In vivo confocal microscopic characteristics of crystalline kerstopathy in patients with monoclonal genmopathy. Report of two cases. Indian Journal of Ophthalmology. 2014, 62, 938. 1.1 17 114 In vivo confocal microscopic characteristics of crystalline kerstopathy in patients with monoclonal log genmopathy. Report of two cases. Indian Journal of Ophthalmology. 2014, 62, 938. 1.1 17 115 LOCAL Renin-Angiotensin System in Normal Hematopoletic and Multiple Myeloma-Related Progenitor 0.5 6 116 Local Renin-Angiotensin System in Normal Hematology. 2014, 36, e410-e411. 0.6 8 117 Increased Soluble Selectins as a Reflection of Achivated Platelets and Endothelium in Legg-Calve-Perthes Disease. Journal of Pediatric Hematology.Oncology. 2014, 36, e410-e411. 0.6 8 116 Plateletcrit. Herz.	109		0.3	3
111 and Experimental Medicine, 2015, 8, 22515-9. L3 1 112 The factors affecting early death after the initial therapy of acute myeloid leukemia. International L3 5 113 Next Ceneration Nanomedicine in the Cenesis of 3-60-Ankaferd Blood Stopper Nanohemostatä-G Clinical and L7 1 114 In vivo confocal microscopic characteristics of crystalline keratopathy in patients with monoclonal L1 17 114 In vivo confocal microscopic characteristics of crystalline keratopathy in patients with monoclonal L1 17 114 In vivo confocal microscopic characteristics of crystalline keratopathy in patients with monoclonal L1 17 115 ILUKING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOD L3 12 116 Local Renin-Angiotensin System in Normal Hematology and Infectious Diseases, 2014, 6, e2014009. L3 12 117 Legg Calve-Perthes Disease. Journal of Pediatric Hematology, 2014, 36, e410-e411. 0.6 8 118 Tratamiento effectivo de la hemoptysis Wa Endobronchial Application of Ankaferd Hemostal, sico Ankaferd. 0.8 5 119 Plateleterrit. Herz, 2014, 39, 142-148. 1.1 45 120 Effective Management of Hemophysis Via Endobronchial Applicati	110	Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms. Turkish Journal of Haematology, 2015, 32, 163-167.	0.5	5
112 journal of Clinical and Experimental Medicine, 2015, 8, 22564-9. 1.3 5 113 Next Ceneration Nanomedicine in the Genesis of & GeAnkaferd Blood Stopper Nanohemostat& Clinical and Applied Thrombosis/Hemostasis, 2014, 20, 456-457. 1.7 1 114 In vivo confocal microscopic characteristics of crystalline keratopathy in patients with monoclonal gammopathy: Report of two cesses. Indian Journal of Ophthalmology, 2014, 62, 938. 1.1 17 115 MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML). Mediterranean Journal of Hematology and Infectious Diseases, 2014, 6, e2014009. 1.3 12 116 Local Renin-Angiotensin System in Normal Hematopoietic and Multiple Myeloma-Related Progenitor Cells. Turkish Journal of Heematology, 2014, 31, 136-142. 0.5 6 117 Increased Soluble Selectins as a Reflection of Activated Platelets and Endothelium in Legg-Calve-Perthes Disease. Journal of Pediatric Hematology/Oncology, 2014, 36, e410-e411. 0.6 8 118 Tratamiento effectivo de la hemoptysis mediante aplicacitÃ'an endobronquial del hemostăţisco Ankaferd. 0.8 5 120 Effective Management of Hemoptysis Via Endobronchial Application of Ankaferd Hemostat. Archivos 0.8 5 121 Plateletcrit. Herz, 2014, 30, 407-409. 0.8 5 122 Effective Management of	111	Clinicopathological associations of acquired erythroblastopenia. International Journal of Clinical and Experimental Medicine, 2015, 8, 22515-9.	1.3	1
113 Applied Thrombosis/Hemostasis, 2014, 20, 456-457. 1.7 1.7 114 In vivo confocal microscopic characteristics of crystalline keratopathy in patients with monoclonal 1.1 1.7 114 In vivo confocal microscopic characteristics of crystalline keratopathy in patients with monoclonal 1.1 1.7 115 MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID 1.3 1.2 116 Local Renin-Angiotensin System in Normal Hematopojetic and Multiple Myeloma-Related Progenitor 0.5 6 117 legg-Calve-Perthes Disease, Journal of Activated Platelets and Endothellum in 0.6 8 118 Tratamiento effectivo de la hemoptisis mediante aplicaciA³n endobronquial del hemostÂjsico Ankaferd. 0.8 7 119 Plateletcrit. Herz, 2014, 39, 142-148. 1.1 45 120 Effective Management of Hemoptysis Via Endobronchial Application of Ankaferd Hemostat. Archivos 0.8 5 121 Plateletcrit. Herz, 2014, 39, 142-148. 1.9 68 122 Effective Management of Hemoptysis Via Endobronchial Application of Ankaferd Hemostat. Archivos 0.8 5 122 Plateletcrit. Herz, 2014, 63, 244-245. 1.9 68 123	112		1.3	5
114 gammopathy: Report of two cases. Indian journal of Ophthalmology, 2014, 62, 938. 1.1 17 115 MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID 1.3 12 116 Local Renin-Angiotensin System in Normal Hematology and Infectious Diseases, 2014, 6, e2014009. 1.3 12 116 Local Renin-Angiotensin System in Normal Hematopoletic and Multiple Myeloma-Related Progenitor 0.5 6 117 Legg Calve-Perthes Disease. Journal of Padiatric Hematology/Oncology, 2014, 36, e410-e411. 0.6 8 118 Tratamiento efectivo de la hemoptisis mediante aplicaciÃ ³ n endobronquial del hemostĂjsico Ankaferd. 0.8 7 119 Plateleterit. Herz, 2014, 39, 142-148. 1.1 45 120 Effective Management of Hemoptysis Via Endobronchial Application of Ankaferd Hemostat. Archivos 0.8 5 120 Deffective Management of Hemoptysis Via Endobronchial Application of Ankaferd Hemostat. Archivos 0.8 5 121 Plateleterit. Herz, 2014, 63, 244-245. 1.9 68 122 Authorsã€ [™] response to the comments on automated platelet analyses by Dr Beyan. Journal of 1.9 0 122 Authorsã€ [™] response to the comments on automated platelet analyses by Dr Beyan. Journal of </td <td>113</td> <td></td> <td>1.7</td> <td>1</td>	113		1.7	1
IIIS LEUKEMIA (CML). Mediterranean Journal of Hematology and Infectious Diseases, 2014, 6, e2014009. I.S 12 III6 Local Renin-Angiotensin System in Normal Hematopoietic and Multiple Myeloma-Related Progenitor Cells. Turkish Journal of Haematology, 2014, 31, 136-142. 0.5 6 II17 Increased Soluble Selectins as a Reflection of Activated Platelets and Endothelium in Legg Calve-Petrhes Disease. Journal of Pediatric Hematology/Oncology, 2014, 36, e410-e411. 0.6 8 II18 Tratamiento efectivo de la hemoptisis mediante aplicaciÃ ³ n endobronquial del hemostÂţsico Ankaferd. 0.8 7 II19 Plateletcrit. Herz, 2014, 39, 142-148. I.1 45 I20 Effective Management of Hemoptysis Via Endobronchial Application of Ankaferd Hemostat. Archivos 0.8 5 I21 Plateletcrit and red cell distribution width are independent predictors of the slow coronary flow phenomenon. Journal of Cardiology, 2014, 63, 112-118. I.9 68 I22 Authorsã C ^M response to the comments on automated platelet analyses by Dr Beyan. Journal of Cardiology, 2014, 63, 244-245. I.4 1 I23 Massive Life-Threatening Hemorrhages Due to Toxic Oral Intake of 3750 Mg Dabigatran Etexilate As a Sucide Attempt and the Clinical Management. Blood, 2014, 124, 5091-5091. I.4 1 I24 Evaluation of Anti-Neoplastic Effects of a New Hemostatic Agent Ankaferd Bl	114	In vivo confocal microscopic characteristics of crystalline keratopathy in patients with monoclonal gammopathy: Report of two cases. Indian Journal of Ophthalmology, 2014, 62, 938.	1.1	17
116 Cells. Turkish Journal of Haematology, 2014, 31, 136-142. 0.3 6 117 Increased Soluble Selectins as a Reflection of Activated Platelets and Endothelium in Legg-Calve-Perthes Disease. Journal of Pediatric Hematology/Oncology, 2014, 36, e410-e411. 0.6 8 118 Tratamiento efectivo de la hemoptisis mediante aplicaciÃ ³ n endobronquial del hemostÃjsico Ankaferd. 0.8 7 119 Plateletcrit. Herz, 2014, 39, 142-148. 1.1 45 120 Effective Management of Hemoptysis Via Endobronchial Application of Ankaferd Hemostat. Archivos 0.8 5 121 Plateletcrit. Herz, 2014, 59, 407-409. 0.8 5 121 Plateletcrit and red cell distribution width are independent predictors of the slow coronary flow phenomenon. Journal of Cardiology, 2014, 63, 112-118. 1.9 68 122 Authorsãe ™ response to the comments on automated platelet analyses by Dr Beyan. Journal of Cardiology, 2014, 63, 244-245. 1.9 0 123 Massive Life-Threatening Hemorrhages Due to Toxic Oral Intake of 3750 Mg Dabigatran Etexilate As a L.4 1 124 Evaluation of Anti-Neoplastic Effects of a New Hemostatic Agent Ankaferd Blood Stopper on Myeloma Legil Line and Plasmocytoma Development in Balb/c Mice: Results of the First in Vitro and in Vivo Study. Blood, 2014, 124, 5728-5728. 1.4 3	115		1.3	12
117 Legg-Calve-Perthes Disease. Journal of Pediatric Hematology/Oncology, 2014, 36, e410-e411. 0.6 8 118 Tratamiento efectivo de la hemoptisis mediante aplicación endobronquial del hemostÃjsico Ankaferd. Archivos De Bronconeumologia, 2014, 50, 407-409. 0.8 7 119 Plateletcrit. Herz, 2014, 39, 142-148. 1.1 45 120 Effective Management of Hemoptysis Via Endobronchial Application of Ankaferd Hemostat. Archivos De Bronconeumologia, 2014, 50, 407-409. 0.8 5 121 Plateletcrit and red cell distribution width are independent predictors of the slow coronary flow phenomenon. Journal of Cardiology, 2014, 63, 112-118. 1.9 68 122 Authors' response to the comments on automated platelet analyses by Dr Beyan. Journal of Cardiology, 2014, 63, 244-245. 1.9 0 123 Massive Life-Threatening Hemorrhages Due to Toxic Oral Intake of 3750 Mg Dabigatran Etexilate As a Suicide Attempt and the Clinical Management. Blood, 2014, 124, 5091-5091. 1.4 1 124 Evaluation of Anti-Neoplastic Effects of a New Hemostatic Agent Ankaferd Blood Stopper on Myeloma Cell Line and Plasmocytoma Development in Babl/c Mice: Results of the First in Vitro and in Vivo Study. Blood, 2014, 124, 5728-5728. 1.4 3 1124 High-dose chemotherapy and autologous peripheral blood stem cell (PBSC) transplantation with 1.4 3	116		0.5	6
118 Archivos De Bronconeumologia, 2014, 50, 407-409. 0.8 7 119 Plateletcrit. Herz, 2014, 39, 142-148. 1.1 45 120 Effective Management of Hemoptysis Via Endobronchial Application of Ankaferd Hemostat. Archivos 0.8 5 121 Plateletcrit and red cell distribution width are independent predictors of the slow coronary flow phenomenon. Journal of Cardiology, 2014, 63, 112-118. 1.9 68 122 Authors' response to the comments on automated platelet analyses by Dr Beyan. Journal of Cardiology, 2014, 63, 244-245. 1.9 0 123 Massive Life-Threatening Hemorrhages Due to Toxic Oral Intake of 3750 Mg Dabigatran Etexilate As a Suicide Attempt and the Clinical Management. Blood, 2014, 124, 5091-5091. 1.4 1 124 Evaluation of Anti-Neoplastic Effects of a New Hemostatic Agent Ankaferd Blood Stopper on Myeloma Cell Line and Plasmocytoma Development in Balb/c Mice: Results of the First in Vitro and in Vivo Study. 1.4 3 125 High-dose chemotherapy and autologous peripheral blood stem cell (PBSC) transplantation with 1.6 0	117		0.6	8
120Effective Management of Hemoptysis Via Endobronchial Application of Ankaferd Hemostat. Archivos De Bronconeumologia, 2014, 50, 407-409.0.85121Plateletcrit and red cell distribution width are independent predictors of the slow coronary flow phenomenon. Journal of Cardiology, 2014, 63, 112-118.1.968122Authors' response to the comments on automated platelet analyses by Dr Beyan. Journal of Cardiology, 2014, 63, 244-245.1.90123Massive Life-Threatening Hemorrhages Due to Toxic Oral Intake of 3750 Mg Dabigatran Etexilate As a Suicide Attempt and the Clinical Management. Blood, 2014, 124, 5091-5091.1.41124Evaluation of Anti-Neoplastic Effects of a New Hemostatic Agent Ankaferd Blood Stopper on Myeloma Cell Line and Plasmocytoma Development in Balb/c Mice: Results of the First in Vitro and in Vivo Study.1.43125High-dose chemotherapy and autologous peripheral blood stem cell (PBSC) transplantation with1.40	118	Tratamiento efectivo de la hemoptisis mediante aplicación endobronquial del hemostásico Ankaferd. Archivos De Bronconeumologia, 2014, 50, 407-409.	0.8	7
120 De Bronconeumologia, 2014, 50, 407-409. 0.8 5 121 Plateletcrit and red cell distribution width are independent predictors of the slow coronary flow phenomenon. Journal of Cardiology, 2014, 63, 112-118. 1.9 68 122 Authors' response to the comments on automated platelet analyses by Dr Beyan. Journal of Cardiology, 2014, 63, 244-245. 1.9 0 123 Massive Life-Threatening Hemorrhages Due to Toxic Oral Intake of 3750 Mg Dabigatran Etexilate As a Suicide Attempt and the Clinical Management. Blood, 2014, 124, 5091-5091. 1.4 1 124 Evaluation of Anti-Neoplastic Effects of a New Hemostatic Agent Ankaferd Blood Stopper on Myeloma Cell Line and Plasmocytoma Development in Balb/c Mice: Results of the First in Vitro and in Vivo Study. 1.4 3 125 High-dose chemotherapy and autologous peripheral blood stem cell (PBSC) transplantation with 1.6 0	119	Plateletcrit. Herz, 2014, 39, 142-148.	1.1	45
121 phenomenon. Journal of Cardiology, 2014, 63, 112-118. 1.9 68 122 Authors' response to the comments on automated platelet analyses by Dr Beyan. Journal of Cardiology, 2014, 63, 244-245. 1.9 0 123 Massive Life-Threatening Hemorrhages Due to Toxic Oral Intake of 3750 Mg Dabigatran Etexilate As a Suicide Attempt and the Clinical Management. Blood, 2014, 124, 5091-5091. 1.4 1 124 Evaluation of Anti-Neoplastic Effects of a New Hemostatic Agent Ankaferd Blood Stopper on Myeloma Cell Line and Plasmocytoma Development in Balb/c Mice: Results of the First in Vitro and in Vivo Study. 1.4 3 125 High-dose chemotherapy and autologous peripheral blood stem cell (PBSC) transplantation with 1.6 0	120	Effective Management of Hemoptysis Via Endobronchial Application of Ankaferd Hemostat. Archivos De Bronconeumologia, 2014, 50, 407-409.	0.8	5
122 Cardiology, 2014, 63, 244-245. 1.9 0 123 Massive Life-Threatening Hemorrhages Due to Toxic Oral Intake of 3750 Mg Dabigatran Etexilate As a Suicide Attempt and the Clinical Management. Blood, 2014, 124, 5091-5091. 1.4 1 124 Evaluation of Anti-Neoplastic Effects of a New Hemostatic Agent Ankaferd Blood Stopper on Myeloma Cell Line and Plasmocytoma Development in Balb/c Mice: Results of the First in Vitro and in Vivo Study. 1.4 3 125 High-dose chemotherapy and autologous peripheral blood stem cell (PBSC) transplantation with 1.6 0	121		1.9	68
123 Suicide Attempt and the Clinical Management. Blood, 2014, 124, 5091-5091. 1.4 1 124 Evaluation of Anti-Neoplastic Effects of a New Hemostatic Agent Ankaferd Blood Stopper on Myeloma 1.4 3 124 Cell Line and Plasmocytoma Development in Balb/c Mice: Results of the First in Vitro and in Vivo Study. 1.4 3 125 High-dose chemotherapy and autologous peripheral blood stem cell (PBSC) transplantation with 1.6 0	122		1.9	0
124 Cell Line and Plasmocytoma Development in Balb/c Mice: Results of the First in Vitro and in Vivo Study. 1.4 3 Blood, 2014, 124, 5728-5728. High-dose chemotherapy and autologous peripheral blood stem cell (PBSC) transplantation with 1.4 3	123		1.4	1
	124	Cell Line and Plasmocytoma Development in Balb/c Mice: Results of the First in Vitro and in Vivo Study.	1.4	3
	125		1.6	0

Lower Doses of Plerixafor Use Is Sufficient to Effectively Mobilize PBSC (Peripheral Blood) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62 Td (H

#	Article	IF	CITATIONS
127	Rebound Thrombocytosis Is an Independent Predictor of Good Prognosis in AML Patients Attaining First Complete Remission. Blood, 2014, 124, 2283-2283.	1.4	Ο
128	Nilotinib Results in Improved Rates of Molecular Response in Turkish Newly Diagnosed CML-CP Patients: A 24-Month Update. Blood, 2014, 124, 5532-5532.	1.4	0
129	Prognostic Factors for Survival of Elderly Patients with Acute Myeloid Leukemia after Intensive Chemotherapy: Validation of 3 Popular Prognostic Models. Blood, 2014, 124, 5332-5332.	1.4	Ο
130	Short-Term Effects of Ankaferd Hemostat for Renal Artery Embolization: An Experimental Study. CardioVascular and Interventional Radiology, 2013, 36, 498-504.	2.0	5
131	Evaluation of the mean platelet volume in secondary amyloidosis due to familial Mediterranean fever. Rheumatology International, 2013, 33, 2555-2559.	3.0	4
132	Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: A single center experience. Transfusion and Apheresis Science, 2013, 49, 590-599.	1.0	9
133	Circulating CD4+CD25+ Regulatory T Cells in the Pathobiology of Ulcerative Colitis and Concurrent Primary Sclerosing Cholangitis. Digestive Diseases and Sciences, 2013, 58, 1250-1255.	2.3	11
134	Current concerns of undertreatment and overtreatment in chronic myeloid leukemia based on European LeukemiaNet 2013 recommendations. Expert Opinion on Pharmacotherapy, 2013, 14, 2005-2010.	1.8	27
135	Topical Ankaferd hemostat for the management of clinical bleeding plus hemorrhagic diathesis. Gastrointestinal Intervention, 2013, 2, 127.	0.1	0
136	Echocardiographic Dilemma: Misleading Thrombus Appearance Due to Cavitation With Intravascular Hemolysis on a Mechanical Prosthetic Valve. Canadian Journal of Cardiology, 2013, 29, 403.e1-403.e2.	1.7	1
137	The therapeutic goals of essential thrombocythemia under the clouds of over-treatment and under-treatment. Expert Opinion on Pharmacotherapy, 2013, 14, 1431-1436.	1.8	4
138	Local bone marrow renin–angiotensin system in primitive, definitive and neoplastic haematopoiesis. Clinical Science, 2013, 124, 307-323.	4.3	41
139	EUTOS CML prognostic scoring system predicts ELN-based â€ [~] event-free survival' better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate. Hematology, 2013, 18, 247-252.	1.5	31
140	Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors. Turkish Journal of Haematology, 2013, 30, 247-255.	0.5	5
141	Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients. Turkish Journal of Haematology, 2013, 30, 351-358.	0.5	14
142	Co-expression of t(15;17) and t(8;21) in a Case of Acute Promyelocytic Leukemia: Review of the Literature. Turkish Journal of Haematology, 2013, 30, 400-404.	0.5	6
143	The Impact of Eltrombopag Administration on the Clinical Course of Severe Refractory Fatal Acquired Aplastic Anemia. Turkish Journal of Haematology, 2013, 30, 328-330.	0.5	4
144	Local hematopoietic renin-angiotensin system in myeloid versus lymphoid hematological neoplastic disorders. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2013, 14, 308-314.	1.7	10

#	Article	IF	CITATIONS
145	Hyper-CVAD Regimen in Routine Management of Adult Acute Lymphoblastic Leukemia: A Retrospective Multicenter Study. Acta Haematologica, 2013, 130, 199-205.	1.4	22
146	Key Decision Just After 3 Months Following TKI Initiation in CML: Better and not Difficult. UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, 2013, 23, 1-2.	0.1	0
147	Generation of Chimeric "ABS Nanohemostat―Complex and Comparing Its Histomorphological <i>In Vivo</i> Effects to the Traditional Ankaferd Hemostat in Controlled Experimental Partial Nephrectomy Model. International Journal of Biomaterials, 2013, 2013, 1-10.	2.4	6
148	Long-Term Sustained Hemorrhage Due to Bone Marrow Biopsy Successfully Treated With Topical Ankaferd Hemostat in a Bleeding-Prone Patient With Secondary Amyloidosis. Clinical and Applied Thrombosis/Hemostasis, 2013, 19, 338-340.	1.7	1
149	The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood, 2013, 121, 4439-4442.	1.4	546
150	Oral High-Dose Ankaferd Administration Effects on Gastrointestinal System. International Journal of Medical Sciences, 2013, 10, 451-456.	2.5	7
151	Experience With BFM 95 Pediatric Regimen In Adult ACUTE Lymphoblastic Leukemia. Blood, 2013, 122, 5015-5015.	1.4	1
152	Use Of Nilotinib As a First Line Treatment In Adult Patients With Philadelphia Chromosome-Positive and Chronic Phase Myeloid Leukemia. Blood, 2013, 122, 2742-2742.	1.4	0
153	Unusual Extramedullary Recurrence and Renal Relapse Despite Complete Chimerysm after Allografting in Ph+ ALL. UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, 2012, 22, 46-50.	0.1	0
154	Prohemostatic and Antithrombin Activities of Ankaferd Hemostat Are Linked to Fibrinogen Gamma Chain and Prothrombin by Functional Proteomic Analyses. Clinical and Applied Thrombosis/Hemostasis, 2012, 18, 604-610.	1.7	22
155	Striking Promotion of the in vitro Myeloma Monoclonal Immunoglobulin Aggregation by Ankaferd Hemostat. UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, 2012, 22, 15-22.	0.1	2
156	A Placebo-Controlled, Randomized, Double-Blinded, Cross-Over Phase-I Clinical Study Indicating the Safety of Topical Ankaferd Hemostat in Healthy Volunteers. UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, 2012, 22, 267-274.	0.1	4
157	Histopathological Alterations in the Kidney Tissue Following Topical Ankaferd Hemostat Application in a Rat Renal Injury Model. UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, 2012, 22, 275-281.	0.1	1
158	The Clinical Impact of Low Doses of Dasatinib in Patients with Chronic Myeloid Leukemia. UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, 2012, 22, 8-14.	0.1	1
159	Effective Molecular Monitoring and the Proper Management of Pleural Effusion During the First-Line Dasatinib Administration in CML. UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, 2012, 22, 1-7.	0.1	1
160	Controlling of upper gastrointestinal bleeding associated with severe immune thrombocytopenia via topical adjunctive application of Ankaferd blood stopper. Blood Coagulation and Fibrinolysis, 2012, 23, 464.	1.0	3
161	Increased mean platelet volume (MPV) indicating the vascular risk in Alzheimer's disease (AD). Archives of Gerontology and Geriatrics, 2012, 55, 257-260.	3.0	31
162	Increased ferritin levels could reflect ongoing aging-associated inflammation and may obscure underlying iron deficiency in the geriatric population. European Geriatric Medicine, 2012, 3, 277-280.	2.8	20

#	Article	IF	CITATIONS
163	Topical Ankaferd hemostat application for the management of oral cavity bleedings in children with hemorrhagic diathesis. Blood Coagulation and Fibrinolysis, 2012, 23, 494-497.	1.0	12
164	Iron deficiency can cause cognitive impairment in geriatric patients. Journal of Nutrition, Health and Aging, 2012, 16, 220-224.	3.3	61
165	Pleiotropic cellular, hemostatic, and biological actions of Ankaferd hemostat. Critical Reviews in Oncology/Hematology, 2012, 83, 21-34.	4.4	63
166	Beneficial effects of Ankaferd Blood Stopper on caustic esophageal injuries: an experimental model. Ecological Management and Restoration, 2012, 25, 188-194.	0.4	24
167	Molecular Basis of Ankaferd-Induced Hemostasis in the Management of Sternal Bleeding. Heart Surgery Forum, 2012, 15, E305-E305.	0.5	2
168	Percutaneous ankaferd injection to in vivo liver tissue in comparison to ethanol in an experimental rat model. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 549-553.	1.5	9
169	Increased ACE in extrahepatic cholangiocarcinoma as a clue for activated RAS in biliary neoplasms. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 644-649.	1.5	18
170	Ankaferd Blood Stopper in GI bleeding: alternative for everything?. Gastrointestinal Endoscopy, 2011, 73, 185-186.	1.0	8
171	Ankaferd hemostat for the management of tumoral GI bleeding. Gastrointestinal Endoscopy, 2011, 73, 1072-1073.	1.0	8
172	Ankaferd Blood Stopper Is More Effective Than Adrenaline Plus Lidocaine and Gelatin Foam in the Treatment of Epistaxis in Rabbits. Current Therapeutic Research, 2011, 72, 185-194.	1.2	9
173	Identification of clinical and simple laboratory variables predicting responsible gastrointestinal lesions in patients with iron deficiency anemia. International Journal of Medical Sciences, 2011, 8, 30-38.	2.5	14
174	Ankaferd hemostat in the management of gastrointestinal hemorrhages. World Journal of Gastroenterology, 2011, 17, 3962.	3.3	41
175	Elevated Levels of Circulating Angiotensin Converting Enzyme in Patients with Hepatoportal Sclerosis. Digestive Diseases and Sciences, 2011, 56, 2160-2165.	2.3	17
176	Upper Gastrointestinal Bleeding in a Patient With Defective Hemostasis Successfully Treated with Ankaferd Blood Stopper. Phytotherapy Research, 2011, 25, 312-313.	5.8	26
177	Local Bone Marrow Renin-Angiotensin System and Atherosclerosis. Cardiology Research and Practice, 2011, 2011, 1-10.	1.1	15
178	A Comparison of Jurkat Cell-Reactive Anti-T Lymphocyte Globulin and Fetal Anti-Thymocyte Globulin Preparations in the Treatment of Aplastic Anemia. Medical Principles and Practice, 2011, 20, 341-344.	2.4	5
179	Angiotensin Converting Enzyme Insertion/Deletion Gene Polymorphisms in Leukemic Hematopoiesis. UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, 2011, 21, 1-9.	0.1	5
180	Basic Hemostatic Parameters in Patients with Long-Term Oral Anticoagulation Undergoing Cholecystectomy. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2011, 21, 417-425.	1.0	4

#	ARTICLE	IF	CITATIONS
181	Reversible Protease-Activated Receptor 1 Downregulation Mediated by Ankaferd Blood Stopper Inducible With Lipopolysaccharides Inside the Human Umbilical Vein Endothelial Cells. Clinical and Applied Thrombosis/Hemostasis, 2011, 17, E165-E170.	1.7	17
182	Eculizumab before and after allogeneic hematopoietic stem cell transplantation in a patient with paroxysmal nocturnal hemoglobinuria. Turkish Journal of Haematology, 2011, 28, 223-227.	0.5	7
183	The effects of Ankaferd Blood Stopper on transcription factors in HUVEC and erythrocyte protein profile. Turkish Journal of Haematology, 2011, 28, 276-85.	0.5	24
184	Dual diverse dynamic reversible actions of Ankaferd on EPCR and PAI-1 inside vascular endothelial cells with and without LPS. Turkish Journal of Haematology, 2011, 29, 361-6.	0.5	8
185	A new candidate as a hemostatic agent for difficult situations during variceal bleeding: Ankaferd blood stopper. Saudi Journal of Gastroenterology, 2011, 17, 145.	1.1	12
186	Topical Ankaferd Bloodstopper in the Management of Critical Bleedings due to Hemorrhagic Diathesis. UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, 2011, 21, 160-165.	0.1	8
187	Surgical and histopathological effects of topical Ankaferd hemostat on major arterial vessel injury related to elevated intra-arterial blood pressure. Turkish Journal of Haematology, 2011, 28, 206-212.	0.5	9
188	Evaluation of a haemostatic agent in rabbits. African Journal of Traditional Complementary and Alternative Medicines, 2011, 8, 61-5.	0.2	4
189	Spinal Myeloid Sarcoma in Two Non-Leukemic Patients. Internal Medicine, 2010, 49, 2493-2497.	0.7	14
190	Antimicrobial activity of Ankaferd Blood Stopper® against nosocomial bacterial pathogens. Open Medicine (Poland), 2010, 5, 198-202.	1.3	18
191	Do All Hemolytic Anemias That Occur After Mitral Valve Repair Require Surgical Treatment?. Clinical Cardiology, 2010, 33, E76-8.	1.8	3
192	Potential biomarkers for vascular damage in ALzheimer's disease: Thrombomodulin and von Willebrand factor. Journal of Nutrition, Health and Aging, 2010, 14, 439-441.	3.3	11
193	Bleeding due to slippage of elastic band during variceal ligation: successful use of Ankaferd blood stopper. Indian Journal of Gastroenterology, 2010, 29, 166-168.	1.4	16
194	Concomitant renal cell carcinoma and lymphoid malignancies: a case series of five patients and review of the literature. Medical Oncology, 2010, 27, 55-58.	2.5	9
195	Clinical features and outcomes of 49 Turkish patients with acute promyelocytic leukemia who received ATRA and anthracyclines (PETHEMA protocol) therapy. Leukemia Research, 2010, 34, e317-e319.	0.8	17
196	Evaluation of the Impact of Treatment on Endothelial Function and Cardiac Performance in Acromegaly. Echocardiography, 2010, 27, 990-996.	0.9	20
197	Ankaferd Blood Stopper for Controlling Gastrointestinal Bleeding due to Distinct Benign Lesions Refractory to Conventional Antihemorrhagic Measures. Canadian Journal of Gastroenterology & Hepatology, 2010, 24, 380-384.	1.7	45
198	Review: Pathobiological aspects of the local bone marrow renin-angiotensin system: a review. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2010, 11, 205-213.	1.7	50

#	Article	IF	CITATIONS
199	Atraumatic Osteonecrosis After Estrogen Replacement Therapy Associated with Low Protein S Level in a Patient with Turner Syndrome. Clinical and Applied Thrombosis/Hemostasis, 2010, 16, 599-601.	1.7	9
200	Ankaferd Blood Stopper for Gastrointestinal Bleeding. Journal of Investigative Surgery, 2010, 23, 239-239.	1.3	14
201	Ultrastructural and Morphological Analyses of the In Vitro and In Vivo Hemostatic Effects of Ankaferd Blood Stopper. Clinical and Applied Thrombosis/Hemostasis, 2010, 16, 446-453.	1.7	56
202	Functional proteomic analysis of Ankaferd® Blood Stopper. Turkish Journal of Haematology, 2010, 27, 70-77.	0.5	38
203	Endoscopic topical application of Ankaferd Blood Stopper for neoplastic gastrointestinal bleeding: A retrospective analysis. Digestive and Liver Disease, 2010, 42, 196-199.	0.9	73
204	A new practical alternative for tumoural gastrointestinal bleeding: Ankaferd blood stopper. Digestive and Liver Disease, 2010, 42, 594-595.	0.9	20
205	An alternative hemostatic method for early GI bleeding caused by anastomotic ulcer. Gastrointestinal Endoscopy, 2010, 72, 902-903.	1.0	5
206	Successful treatment of endoscopic sphincterotomy–induced early hemorrhage with application of Ankaferd Blood Stopper. Gastrointestinal Endoscopy, 2010, 72, 1325-1326.	1.0	13
207	Increased circulating soluble P-selectin in polycystic ovary syndrome. Fertility and Sterility, 2010, 93, 2311-2315.	1.0	14
208	Oral Systemic Administration of Ankaferd Blood Stopper Has No Short-Term Toxicity in an In Vivo Rabbit Experimental Model. Clinical and Applied Thrombosis/Hemostasis, 2010, 16, 533-536.	1.7	38
209	The adhesion molecules of L-selectin and ICAM-1 in thrombocytosis and thrombocytopenia. Platelets, 2010, 21, 49-52.	2.3	4
210	The effect of a new hemostatic agent for difficult cases of non-variceal gastrointestinal bleeding: Ankaferd blood stopper. Hepato-Gastroenterology, 2010, 57, 191-4.	0.5	16
211	Biphasic effects of ankaferd blood stopper on renal tubular apoptosis in the rat partial nephrectomy model representing distinct levels of hemorrhage. Journal of King Abdulaziz University, Islamic Economics, 2010, 31, 864-8.	1.1	15
212	Evaluation of hemostatic effects of Ankaferd as an alternative medicine. Alternative Medicine Review, 2010, 15, 329-36.	3.3	50
213	Hemostatic Efficacy of Ankaferd Blood Stopper® in a Swine Bleeding Model. Medical Principles and Practice, 2009, 18, 165-169.	2.4	76
214	Topical Ankaferd Blood Stopper Administration to Bleeding Gastrointestinal Carcinomas Decreases Tumor Vascularization. American Journal of Gastroenterology, 2009, 104, 2874-2877.	0.4	42
215	Basic parameters of thrombophilia in ocular Behcet disease with posterior segment involvement. British Journal of Ophthalmology, 2009, 93, 1382-1386.	3.9	6
216	Multiple Bulky Cutaneous Plasmacytomas with CNS Relapse without Bone Marrow Involvement during the Course of a Lambda Light Chain Myeloma. Onkologie, 2009, 32, 662-664.	0.8	8

#	Article	IF	CITATIONS
217	Effects of Imatinib Mesylate on Renin–Angiotensin System (RAS) Activity during the Clinical Course of Chronic Myeloid Leukaemia. Journal of International Medical Research, 2009, 37, 1018-1028.	1.0	17
218	Endobronchial application of Ankaferd blood stopper to control profuse lung bleeding leading to hypoxemia and hemodynamic instability. Respiratory Medicine CME, 2009, 2, 144-146.	0.1	24
219	Association of plasma osteopontin levels with coronary calcification evaluated by tomographic coronary calcium scoring. Journal of Bone and Mineral Metabolism, 2009, 27, 591-597.	2.7	11
220	Changes in vascular endothelial growth factor, angiopoietins, and Tie-2 levels with G-CSF stimulation in healthy donors. Annals of Hematology, 2009, 88, 667-671.	1.8	13
221	Serum Stem Cell Factor Level in Renal Transplant Recipients With Posttransplant Erythrocytosis. Artificial Organs, 2009, 33, 1086-1090.	1.9	8
222	Tandem oral, rectal, and nasal administrations of Ankaferd Blood Stopper to control profuse bleeding leading to hemodynamic instability. American Journal of Emergency Medicine, 2009, 27, 631.e1-631.e2.	1.6	43
223	In Vivo Hemostatic Effect of the Medicinal Plant Extract Ankaferd Blood Stopper in Rats Pretreated With Warfarin. Clinical and Applied Thrombosis/Hemostasis, 2009, 15, 270-276.	1.7	69
224	Alterations of von Willebrand Factor and Ristocetin Cofactor Activity During Atrial Fibrillation. Clinical and Applied Thrombosis/Hemostasis, 2009, 15, 103-108.	1.7	3
225	The efficacy of Ankaferd Blood Stopper in antithrombotic drug-induced primary and secondary hemostatic abnormalities of a rat-bleeding model. Blood Coagulation and Fibrinolysis, 2009, 20, 185-190.	1.0	48
226	Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood, 2009, 113, 4497-4504.	1.4	173
227	Extramedullary plasmacytomas of the thyroid and pericardium as initial presentation of multiple myeloma. Annals of Hematology, 2008, 87, 853-854.	1.8	16
228	Haemostatic Actions of the Folkloric Medicinal Plant Extract Ankaferd Blood Stopper®. Journal of International Medical Research, 2008, 36, 163-170.	1.0	256
229	Soluble Platelet Glycoprotein V in Distinct Disease States of Pathological Thrombopoiesis. Journal of the National Medical Association, 2008, 100, 86-90.	0.8	2
230	Thrombomodulin and GFC levels in Legg–Calve–Perthes disease. Hematology, 2008, 13, 324-328.	1.5	16
231	Successful Management of Bleeding Due to Solitary Rectal Ulcer via Topical Application of Ankaferd Blood Stopper. Journal of Alternative and Complementary Medicine, 2008, 14, 1073-1074.	2.1	60
232	Endoscopic Application of Ankaferd Blood Stopper as a Novel Experimental Treatment Modality for Upper Gastrointestinal Bleeding: A Case Report. American Journal of Gastroenterology, 2008, 103, 2156-2158.	0.4	90
233	Severe Arterial Thrombophilia Associated With a Homozygous MTHFR Gene Mutation (A1298C) in a Young Man With Klinefelter Syndrome. Clinical and Applied Thrombosis/Hemostasis, 2008, 14, 369-371.	1.7	13
234	Fenofibrate improves endothelial function and decreases thrombin-activatable fibrinolysis inhibitor concentration in metabolic syndrome. Blood Coagulation and Fibrinolysis, 2008, 19, 310-314.	1.0	25

#	Article	IF	CITATIONS
235	Effect of platelet count on secretion capacity: formulization and use of the formulae for evaluation of platelet secretion in thrombocytopenic patients. Blood Coagulation and Fibrinolysis, 2008, 19, 633-637.	1.0	5
236	Evidence for Higher Red Blood Cell Mass in Persons With Unconjugated Hyperbilirubinemia and Gilbert's Syndrome. American Journal of the Medical Sciences, 2008, 335, 115-119.	1.1	16
237	Functional Proteomics of Ankaferd Blood Stopper. Blood, 2008, 112, 4103-4103.	1.4	7
238	Haemostatic actions of the folkloric medicinal plant extract Ankaferd Blood Stopper. J Int Med Res 2008; 36:163-170. Journal of International Medical Research, 2008, 36, 1447-8; author reply 1448-9.	1.0	8
239	Short-Term Hemostatic Safety of Strontium Ranelate Treatment in Elderly Women with Osteoporosis. Annals of Pharmacotherapy, 2007, 41, 41-45.	1.9	11
240	Renin-angiotensin system expression in the K562 human erythroleukaemic cell line. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2007, 8, 145-147.	1.7	13
241	Lack of Platelet Activation Reflected by Circulating Soluble Glycoprotein V in Pre-eclampsia. Journal of International Medical Research, 2007, 35, 704-708.	1.0	3
242	Warfarin-induced skin necrosis and leukocytoclastic vasculitis in a patient with acquired protein C and protein S deficiency. Blood Coagulation and Fibrinolysis, 2007, 18, 805-806.	1.0	17
243	Effects of Acute Exercise on Fibrinolysis and Coagulation in Patients With Coronary Artery Disease. International Heart Journal, 2007, 48, 277-285.	1.0	9
244	Chemotherapy and imatinib-induced molecular remission in lymphoid blast crisis after 20 years of "untreated―chronic myeloid leukemia. American Journal of Hematology, 2007, 82, 333-333.	4.1	0
245	Alterations in the â€~local umbilical cord blood renin-angiotensin system' during pre-eclampsia. Acta Obstetricia Et Gynecologica Scandinavica, 2007, 86, 1193-1199.	2.8	9
246	Haemostatic Actions of the Folkloric Medicinal Plant Extract, Ankaferd Blood Stopper Blood, 2007, 110, 3943-3943.	1.4	3
247	Overexpression of the local bone marrow renin-angiotensin system in acute myeloid leukemia. Journal of the National Medical Association, 2007, 99, 57-63.	0.8	28
248	Angiotensin-converting enzyme expression of the lymphoma-associated macrophages in the lymph nodes of Hodgkin's disease. Journal of the National Medical Association, 2007, 99, 1243-4, 1246-7.	0.8	13
249	Over-expression of angiotensin-converting enzyme (CD 143) on leukemic blasts as a clue for the activated local bone marrow RAS in AML. Leukemia and Lymphoma, 2006, 47, 891-896.	1.3	34
250	Changing clinical manifestations of a T-peripheral lymphoma: From hypereosinophilic syndrome to questionable Kimura's disease resulting in parotid mass. Leukemia and Lymphoma, 2006, 47, 357-360.	1.3	9
251	Rethinking leptin and insulin action: Therapeutic opportunities for diabetes. International Journal of Biochemistry and Cell Biology, 2006, 38, 820-830.	2.8	49
252	Unusual extramedullary recurrences and breast relapse despite hepatic GVHD after allografting in Ph+-ALL. Hematology, 2006, 11, 105-107.	1.5	9

#	Article	IF	CITATIONS
253	The Search for a Common Thrombophilic State During the Active State of Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 2006, 40, 809-813.	2.2	19
254	Unchanged global fibrinolytic capacity during the course of hematopoietic stem cell transplantation. Blood Coagulation and Fibrinolysis, 2006, 17, 47-51.	1.0	1
255	Tonsillar abscess formation due to herpes simplex type-1 in a severely immunocompromised stem cell transplant patient with chronic myeloid leukemia. Transplant Infectious Disease, 2006, 8, 166-170.	1.7	9
256	Absence d'association entreÂfièvre méditerranéenne familiale etÂpolymorphisme duÂgène deÂl'enzyme deÂconversion deÂl'angiotensine. Revue Du Rhumatisme (Edition Francaise), 2006, 73, 523-525.	0.0	0
257	Spontaneous tumor lysis syndrome in a patient with diffuse large B cell lymphoma and Richter syndrome. Annals of Hematology, 2006, 85, 183-184.	1.8	19
258	Increased serum thrombopoietin concentration in systemic sclerosis associated with myelofibrosis and thrombocytosis. Joint Bone Spine, 2006, 73, 122-123.	1.6	4
259	Lack ofÂassociation between familial Mediterranean fever andÂangiotensin converting enzyme gene polymorphism. Joint Bone Spine, 2006, 73, 334-336.	1.6	2
260	Plasma Soluble Osteopontin Concentrations Are Increased in Patients With Rheumatic Mitral Stenosis and Associated With the Severity of Mitral Valve Calcium. American Journal of Cardiology, 2006, 98, 817-820.	1.6	17
261	Decrements in the Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Levels in Association with Orlistat Treatment in Obesity. Clinical and Applied Thrombosis/Hemostasis, 2006, 12, 364-368.	1.7	11
262	Myocardial Infarction and Deep Venous Thrombosis in a Young Patient with Behçet Disease. Clinical and Applied Thrombosis/Hemostasis, 2006, 12, 105-109.	1.7	7
263	Predicting Chronic Leukaemias from Assessment of Complete Peripheral Blood Counts. Journal of International Medical Research, 2006, 34, 640-647.	1.0	9
264	No alteration in the PFA-100 in vitro bleeding time induced by the Ginkgo biloba special extract, EGb 761, in elderly patients with mild cognitive impairment. Blood Coagulation and Fibrinolysis, 2005, 16, 349-353.	1.0	10
265	Cytarabine-induced fever complicating the clinical course of leukemia. Anti-Cancer Drugs, 2005, 16, 59-62.	1.4	11
266	Unusual extramedullary relapses under imatinib mesylate treatment in chronic myeloid leukemia. American Journal of Hematology, 2005, 79, 79-80.	4.1	9
267	Systemic toxocariasis presenting with leukemoid reaction and hypereosinophilia. American Journal of Hematology, 2005, 79, 171-171.	4.1	14
268	Local umbilical cord blood renin?angiotensin system. Annals of Hematology, 2005, 84, 277-281.	1.8	24
269	Renin and angiotensin-converting enzyme (ACE) as active components of the local synovial renin-angiotensin system in rheumatoid arthritis. Rheumatology International, 2005, 25, 285-291.	3.0	40
270	Immediate Effects of Fluvastain on Circulating Soluble Endothelial Protein C and Free Tissue Factor Pathway Inhibitor in Acute Coronary Syndromes. Cardiovascular Drugs and Therapy, 2005, 19, 177-181.	2.6	8

#	Article	IF	CITATIONS
271	Increased soluble glycoprotein V concentration during the acute onset of unstable angina pectoris in association with chronic cigarette smoking. Platelets, 2005, 16, 329-333.	2.3	12
272	The Plasma Levels of Prostanoids and Plasminogen Activator Inhibitor-1 in Primary and Secondary Thrombocytosis. Clinical and Applied Thrombosis/Hemostasis, 2005, 11, 197-201.	1.7	8
273	Endogenous thrombopoietin levels during the clinical management of acute myeloid leukaemia. Platelets, 2005, 16, 31-37.	2.3	8
274	ENHANCED TISSUE FACTOR PATHWAY INHIBITOR RESPONSE AS A DEFENSE MECHANISM AGAINST ONGOING LOCAL MICROVASCULAR EVENTS OF LEGG-CALVE-PERTHES DISEASE. Pediatric Hematology and Oncology, 2005, 22, 391-399.	0.8	13
275	Overt gastrointestinal bleeding in haematologic neoplasms. Digestive and Liver Disease, 2005, 37, 917-922.	0.9	24
276	Imatinib mesylate and the management of chronic myeloid leukemia (CML). Turkish Journal of Haematology, 2005, 22, 161-72.	0.5	11
277	Current Debates in Antiphospholipid Syndrome: The Acquired Antibody-Mediated Thrombophilia. Clinical and Applied Thrombosis/Hemostasis, 2004, 10, 89-126.	1.7	17
278	Tumor Lysis Syndrome Associated with Fludarabine Treatment in Chronic Lymphocytic Leukemia. Annals of Pharmacotherapy, 2004, 38, 1319-1320.	1.9	9
279	The Predictability of Factor V Leiden (FV:Q506) Gene Mutation via Clotting-Based Diagnosis of Activated Protein C Resistance. Clinical and Applied Thrombosis/Hemostasis, 2004, 10, 265-270.	1.7	10
280	Protein C Inhibitor and Serum Amyloid a in Immune Thrombocytopaenic Purpura. Journal of International Medical Research, 2004, 32, 62-65.	1.0	4
281	Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state?. Annals of Oncology, 2004, 15, 1622-1626.	1.2	32
282	Angiotensin-converting enzyme gene polymorphism in Beh�et?s disease. Clinical Rheumatology, 2004, 23, 142-146.	2.2	27
283	Successful treatment of rheumatoid arthritis is associated with a reduction in serum sE-selectin and thrombomodulin level. Clinical Rheumatology, 2004, 23, 430-434.	2.2	16
284	Plasminogen activator inhibitor-1 as a link between pathological fibrinolysis and arthritis of Behçet's disease. Rheumatology International, 2004, 24, 98-102.	3.0	14
285	How hematopoietic stem cells know and act in cardiac microenvironment for stem cell plasticity? Impact of local renin–angiotensin systems. Medical Hypotheses, 2004, 63, 866-874.	1.5	31
286	Pathologic thrombopoiesis of rheumatoid arthritis. Rheumatology International, 2003, 23, 49-60.	3.0	54
287	Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis. Arthritis and Rheumatism, 2003, 48, 2256-2261.	6.7	66
288	Towards the understanding of the local hematopoietic bone marrow renin-angiotensin system. International Journal of Biochemistry and Cell Biology, 2003, 35, 867-880.	2.8	104

#	ARTICLE	IF	CITATIONS
289	Decreased Protein Z Concentrations Complicating the Hypercoagulable State of Behqet's Disease. Clinical and Applied Thrombosis/Hemostasis, 2003, 9, 259-263.	1.7	11
290	Bone Marrow and Peripheral Blood C-kit Ligand Concentrations in Patients with Thrombocytosis and Thrombocytopenia. Hematology, 2003, 8, 369-373.	1.5	5
291	Patients with paroxysmal atrial fibrillation but not paroxysmal supraventricular tachycardia display evidence of platelet activation during arrhythmia. Platelets, 2003, 14, 407-411.	2.3	25
292	Diminished Global Fibrinolytic Capacity in Patients With Mitral Valve Prolapse Is Associated With Transient Ischemic Attacks. Clinical and Applied Thrombosis/Hemostasis, 2002, 8, 41-44.	1.7	8
293	Phospholipase A2 activity in platelets of patients with uremia. Platelets, 2002, 13, 415-418.	2.3	33
294	Autoimmune hemolytic anemia in Philadelphia positive chronic myeloid leukemia with t(7;14) anomaly after 5 years of interferon alpha treatment. Haematologia, 2002, 32, 163-167.	0.3	4
295	Effects of Extracorporeal Circulation on Thrombin-Antithrombin III and Prothrombin Fragment 1+2 Levels. Clinical and Applied Thrombosis/Hemostasis, 2002, 8, 61-63.	1.7	1
296	Thrombocytopenia Complicating the Clinical Course of Leptospiral Infection. Journal of International Medical Research, 2002, 30, 535-540.	1.0	25
297	Global Fibrinolytic Capacity Is Decreased in Polycystic Ovary Syndrome, Suggesting a Prothrombotic State. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3871-3875.	3.6	118
298	Circulating and Local Bone Marrow Renin-angiotensin System in Leukemic Hematopoiesis: Preliminary Evidences. Hematology, 2002, 7, 75-82.	1.5	33
299	Thrombopoietin as a Drug: Biologic Expectations, Clinical Realities, and Future Directions. Clinical and Applied Thrombosis/Hemostasis, 2002, 8, 193-212.	1.7	25
300	Plasma Thrombospondin in Immune Thrombocytopenic Purpura. Journal of International Medical Research, 2002, 30, 52-55.	1.0	4
301	Circulating Thrombopoietin in Clonal Versus Reactive Thrombocytosis. Hematology, 2002, 7, 9-12.	1.5	13
302	Rational use of the PFA-100 device for screening of platelet function disorders and von Willebrand disease. Blood Coagulation and Fibrinolysis, 2002, 13, 349-353.	1.0	36
303	Proinflammatory and Hematopoietic Cytokines in Reactive and Clonal Thrombycytosis. Southern Medical Journal, 2002, 95, 565-566.	0.7	1
304	Pathological haemostasis and â€~prothrombotic state' in Behçet's disease. Thrombosis Research, 2002, 105, 125-133.	1.7	107
305	Old antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Medical Hypotheses, 2002, 59, 344-348.	1.5	46
306	Effects of short-term atorvastatin treatment on global fibrinolytic capacity, and sL-selectin and sFas levels in hyperlipidemic patients with coronary artery disease. International Journal of Cardiology, 2002, 84, 227-231.	1.7	32

#	Article	IF	CITATIONS
307	Piebaldism associated with congenital dyserythropoietic anemia type II (HEMPAS). American Journal of Hematology, 2002, 69, 210-213.	4.1	5
308	Plasma Thrombopoietin in Patients With Cavernous Transformation of the Portal Vein. International Journal of Hematology, 2002, 75, 91-94.	1.6	1
309	Unchanged global fibrinolytic capacity despite increased factor VIIa activity in Behçet's disease: evidence of a prethrombotic state. Rheumatology International, 2002, 21, 137-140.	3.0	16
310	Hemostatic parameters in Behçet's disease: a reappraisal. Rheumatology International, 2002, 22, 9-15.	3.0	22
311	Increased plasma levels of soluble selectins in patients with unstable angina. International Journal of Cardiology, 2001, 78, 69-73.	1.7	38
312	Cardiac and Great Vessel Thrombosis in Behcet's Disease Internal Medicine, 2001, 40, 68-72.	0.7	20
313	Plasma fibronectin- and thrombospondin-adhesive molecules during acute attacks and attack-free periods of familial Mediterranean fever. Rheumatology International, 2001, 20, 217-220.	3.0	8
314	Two common genetic thrombotic risk factors: Factor V Leiden and prothrombin G20210A in adult Turkish patients with thrombosis. American Journal of Hematology, 2001, 67, 107-111.	4.1	37
315	Soy protein diet significantly improves endothelial function and lipid parameters. Clinical Cardiology, 2001, 24, 711-716.	1.8	37
316	Acute graft-vs-host disease Pathobiology and management. Experimental Hematology, 2001, 29, 259-277.	0.4	307
317	Cytokines, Endothelium, and Adhesive Molecules in Pathologic Thrombopoiesis. Clinical and Applied Thrombosis/Hemostasis, 2001, 7, 126-130.	1.7	10
317 318		1.7 0.9	10 20
	Thrombosis/Hemostasis, 2001, 7, 126-130. Changes in the concentration and distribution of tissue factor pathway inhibitor in Behcet's disease and systemic lupus erythematosus: effect on the prethrombotic state. Annals of the Rheumatic		
318	Thrombosis/Hemostasis, 2001, 7, 126-130. Changes in the concentration and distribution of tissue factor pathway inhibitor in Behcet's disease and systemic lupus erythematosus: effect on the prethrombotic state. Annals of the Rheumatic Diseases, 2001, 60, 1149-1151. Platelet and Leukocyte Deactivation After Intracoronary Stent Placement in Patients Receiving	0.9	20
318 319	 Thrombosis/Hemostasis, 2001, 7, 126-130. Changes in the concentration and distribution of tissue factor pathway inhibitor in Behcet's disease and systemic lupus erythematosus: effect on the prethrombotic state. Annals of the Rheumatic Diseases, 2001, 60, 1149-1151. Platelet and Leukocyte Deactivation After Intracoronary Stent Placement in Patients Receiving Combined Antiplatelet Therapy. Clinical and Applied Thrombosis/Hemostasis, 2001, 7, 116-121. Extent of Coronary Atherosclerosis and Homocysteine Affect Endothelial Markers. Angiology, 2001, 	0.9	20 9
318 319 320	 Thrombosis/Hemostasis, 2001, 7, 126-130. Changes in the concentration and distribution of tissue factor pathway inhibitor in Behcet's disease and systemic lupus erythematosus: effect on the prethrombotic state. Annals of the Rheumatic Diseases, 2001, 60, 1149-1151. Platelet and Leukocyte Deactivation After Intracoronary Stent Placement in Patients Receiving Combined Antiplatelet Therapy. Clinical and Applied Thrombosis/Hemostasis, 2001, 7, 116-121. Extent of Coronary Atherosclerosis and Homocysteine Affect Endothelial Markers. Angiology, 2001, 52, 589-596. Assessment of Autonomic Nervous System Functions in Patients with Vitamin B12 Deficiency by Power Spectral Analysis of Heart Rate Variability. PACE - Pacing and Clinical Electrophysiology, 2000, 23, 	0.9 1.7 1.8	20 9 8
318 319 320 321	Thrombosis/Hemostasis, 2001, 7, 126-130. Changes in the concentration and distribution of tissue factor pathway inhibitor in Behcet's disease and systemic lupus erythematosus: effect on the prethrombotic state. Annals of the Rheumatic Diseases, 2001, 60, 1149-1151. Platelet and Leukocyte Deactivation After Intracoronary Stent Placement in Patients Receiving Combined Antiplatelet Therapy. Clinical and Applied Thrombosis/Hemostasis, 2001, 7, 116-121. Extent of Coronary Atherosclerosis and Homocysteine Affect Endothelial Markers. Angiology, 2001, 52, 589-596. Assessment of Autonomic Nervous System Functions in Patients with Vitamin B12 Deficiency by Power Spectral Analysis of Heart Rate Variability. PACE - Pacing and Clinical Electrophysiology, 2000, 23, 975-978.	0.9 1.7 1.8 1.2	20 9 8 26

#	Article	IF	CITATIONS
325	Thrombosis Involving the Major Veins with Heterozygote Factor V Leiden Mutation as the Only Risk Factor. Clinical and Applied Thrombosis/Hemostasis, 1999, 5, 187-189.	1.7	0
326	Selectins and IL-6 during the Clinical Course of Idiopathic Thrombocytopenic Purpura. Acta Haematologica, 1999, 101, 16-20.	1.4	15
327	Thrombosis and Hemorrhage in Chronic Myeloproliferative Disorders. Clinical and Applied Thrombosis/Hemostasis, 1999, 5, 282-284.	1.7	3
328	Effects of interferon-α2a treatment on serum levels of tumor necrosis factor-α, tumor necrosis factor-α2 receptor, interleukin-2, interleukin-2 receptor, and E-selectin in Behçet's disease. Rheumatology International, 1999, 19, 11-14.	3.0	36
329	Cytokines, Thrombopoietin, and Selectins in Immune Thrombocytopenic Purpura. , 1999, , 213-216.		0
330	<i>In vivo</i> platelet and T-lymphocyte activities during pulmonary tuberculosis. European Respiratory Journal, 1998, 12, 1375-1379.	6.7	27
331	Time to take a healthier view of history. Nature, 1998, 396, 108-108.	27.8	7
332	Activation of Blood Coagulation in Patients With Mitral Stenosis and Sinus Rhythm. American Journal of Cardiology, 1998, 81, 795-797.	1.6	29
333	Behçet's disease as a prethrombotic state. International Journal of Clinical and Laboratory Research, 1998, 28, 200-200.	1.0	2
334	Perianal infections in patients with leukemia. Diseases of the Colon and Rectum, 1998, 41, 81-85.	1.3	53
335	Activated protein C resistance in Behçet's disease. Rheumatology International, 1998, 17, 249-250.	3.0	20
336	Ischemic heart disease in Behçet's syndrome. Rheumatology International, 1998, 17, 251-251.	3.0	1
337	Albendazole-Induced Amegakaryocytic Thrombocytopenic Purpura. Annals of Pharmacotherapy, 1998, 32, 842-842.	1.9	14
338	Pseudospontaneous Platelet Aggregation and Spuriously Elevated Blood Cell Counts in Cryoglobulinemia. Clinical and Applied Thrombosis/Hemostasis, 1998, 4, 209-212.	1.7	1
339	Could Serum Haptoglobin Concentration Be Used as a Marker of Hypersplenism in Chronic Liver Disease?. American Journal of Gastroenterology, 1998, 93, 2641-2642.	0.4	2
340	Haemostasis, Thrombosis, and Endothelium in Behcet's Disease. Acta Haematologica, 1998, 99, 236-237.	1.4	20
341	Hemostatic Problems in Uremia. Blood Purification, 1998, 16, 220-221.	1.8	0
342	MEAN PLATELET VOLUME, PLATELET COUNT AND PLATELET DIMENSIONAL WIDTH DURING HEMODIALYSIS. Thrombosis Research, 1997, 86, 405-408.	1.7	8

#	Article	IF	CITATIONS
343	Haematopoietic Cytokines and Increased Megakaryocytic Proliferation in Chromosome 5q Deletion. Acta Haematologica, 1997, 97, 244-244.	1.4	1
344	Acute tumor lysis syndrome associated with paclitaxel. Annals of Pharmacotherapy, 1997, 31, 1548-1549.	1.9	17
345	The significance and distinct interactions of various growth factors in physiologic and pathologic megakaryocytopoiesis/thrombocytopoiesis. Australian and New Zealand Journal of Medicine, 1997, 27, 191-192.	0.5	5
346	The prethrombotic/hypercoagulable state of Behçet's disease: Comment on the article by Golden et al. Arthritis and Rheumatism, 1997, 40, 1915-1916.	6.7	1
347	Bulky plasmacytoma of the skull with intracranial involvement. , 1997, 54, 173-173.		6
348	Extramedullary acute promyelocytic leukemia. Cancer, 1997, 80, 514-521.	4.1	0
349	A local renin-angiotensin system in the bone marrow. Medical Hypotheses, 1996, 46, 507-510.	1.5	63
350	Coagulation and Fibrinolysis in Amyloid and Non-amyloid Hemodialysis Patients: Assessment of Local Hemostatic Kinetics Within Arteriovenous Fistulas. Clinical and Applied Thrombosis/Hemostasis, 1996, 2, 279-284.	1.7	3
351	Evisceration of the Eye in a Renal Transplant Recipient with Cytomegalovirus Chorioretinitis. American Journal of Nephrology, 1996, 16, 367-368.	3.1	Ο
352	Local Fibrinolysis in Native Arteriovenous Fistulas of Haemodialysis Patients. Blood Purification, 1996, 14, 227-233.	1.8	7
353	Megakaryocyte-Related Interleukins in Reactive Thrombocytosis versus Autonomous Thrombocythemia. Acta Haematologica, 1996, 95, 107-111.	1.4	32
354	Agranulocytosis, Plasmacytosis, and Thrombocytosis Followed by a Leukemoid Reaction Due to Acute Acetaminophen Toxicity. Annals of Pharmacotherapy, 1996, 30, 762-765.	1.9	8
355	Cytokines affecting megakaryocytopoiesis in rheumatoid arthritis with thrombocytosis. Rheumatology International, 1996, 16, 5-8.	3.0	26
356	Chronic lymphocytic leukemia presenting as acute urinary retention due to leukemic in filtration of the prostate. Annals of Hematology, 1996, 73, 143-144.	1.8	15
357	Leukoerythroblastosis following the use of G-CSF. , 1996, 52, 123-124.		7
358	Possible cytokine mechanism of increased megakaryocytic proliferation in 5q- syndrome. American Journal of Hematology, 1996, 52, 124-124.	4.1	4
359	Haemostasic markers in amyloid vs non-amyloid uraemic patients on maintenance haemodialysis. Nephrology, 1996, 2, 273-277.	1.6	2
360	Granulocytic Sarcoma in Acute Promyelocytic Leukemia. Leukemia and Lymphoma, 1996, 22, 183-185.	1.3	9

#	Article	IF	CITATIONS
361	Circulating Thrombomodulin as a Clue of Endothelial Damage in Behçet's Disease. Thrombosis and Haemostasis, 1996, 75, 974-975.	3.4	48
362	Megakaryocytopoietic cytokines in autoimmune thrombocytopenic purpura. American Journal of Hematology, 1995, 49, 265-265.	4.1	14
363	Two cases of extramedullary acute promyelocytic leukemia. Cancer, 1995, 76, 151-152.	4.1	6
364	Eicosanoids in the prethrombotic state of Behçet's disease. Thrombosis Research, 1995, 80, 445-446.	1.7	19
365	Tat and pap in hemodialysis patients: Two cats in a bag?. Thrombosis Research, 1995, 80, 447-449.	1.7	6
366	Interleukinâ€1 β and interleukinâ€6 in clonal versus reactive thrombocytosis. European Journal of Haematology, 1995, 55, 339-340.	2.2	5
367	The Effect of Chronic Angiotensin Converting Enzyme Inhibition on Circulating Prolactin in Systemic Hypertension. Hormone and Metabolic Research, 1994, 26, 491-493.	1.5	2
368	Waldenstrom macroglobulinemia presenting as plasma cell leukemia associated with hyperviscosity syndrome. Medical Science and Discovery, 0, , 390-392.	0.1	0
369	Event-free Survival in Patients with Chronic Myeloid Leukemia Receiving Front-line Imatinib Mesylate. Acta Medica, 0, , .	0.2	0
370	Turkey real-life data: demographic features, treatment results and effects of comorbidities in chronic myeloid leukemia. International Journal of Hematologic Oncology, 0, , .	1.6	0